Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions by unknown
METABOLIC SYNDROME
DIABETOLOGY & 
Zhang et al. Diabetology & Metabolic Syndrome 2014, 6:76
http://www.dmsjournal.com/content/6/1/76RESEARCH Open AccessEffect of glycemic variability on short term
prognosis in acute myocardial infarction subjects
undergoing primary percutaneous coronary
interventions
Jian-wei Zhang1, Ling-jie He2, Shu-jun Cao3, Qing Yang1, Shi-wei Yang1 and Yu-jie Zhou1*Abstract
Objective: Glycemic variability (GV) still remains unclear whether acute glycemic excursion has the important
prognostic significance in ST-segment elevation myocardial infarction (STEMI) patients undergoing p-PCI. So our
aim is to assess the prognostic value of GV in STEMI patients undergoing p-PCI.
Methods: We studied 237 STEMI patients undergoing p-PCI, whose clinical and laboratory data were collected.
We used a continuous glucose monitoring system (CGMS) to measure the fluctuations of blood glucose. Participants
were grouped into diabetes group and non-diabetes group, and grouped into tertiles of mean amplitude of glycemic
excursions (MAGE). The major adverse cardiac events (MACE) of patients was documented during in-hospital and
30-day follow-up. The relationship of MAGE and the incidence of MACE were analyzed.
Results: Data from 237 subjects were incorporated into the statistical analysis, a higher MAGE level was associated
with the higher peak CK-MB values (r = 0.374, P <0.01), and the higher peak cTnI values (r = 0.410, P <0.01). The rate of
composite MACE by MAGE tertiles (<2.37 mmol/l, 2.37-3.65 mmol/l and >3.65 mmol/l) was 7.5% vs. 14.1% vs. 22.8%,
respectively (P = 0.025); STEMI patients with a higher MAGE level had a significantly higher non-IRA revascularization
compared with those with lower MAGE levels (32% vs. 15% vs. 21%, P = 0.037). Moreover, diabetic patients with higher
MAGE level had significantly higher incidence of composite MACE and non-IRA revascularization, non-diabetic subjects
did not show the similar results. In multivariable logistic analysis, the independent predictors of MACE were: MBG, MAGE
and LVEF in diabetic subjects and were MBG and MAGE in nondiabetic subjects. Other factors were not significantly
associated with MACE.
Conclusions: Greater GV is associated with composite MACE and non-IRA revascularization during in-hospital and
30-day follow-up in unadjusted analyses, especially for diabetic subjects. After multivariable logistic analysis, GV remains
an independent prognostic factor for composite MACE in STEMI patients undergoing p-PCI.
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Hyperglycemia is common during acute myocardial
infarction (AMI). It is also a strong predictor of mortality
in AMI patients with and without a history of diabetes
mellitus [1,2]. Meanwhile, some studies have revealed
glycemic variability (GV), which includes both upward and
downward acute glucose changes, is another important
component of dysglycemia [3]. Physiological studies have
suggested several mechanisms through which GV may
adversely impact prognosis in the setting of AMI, including
oxidative stress [4], cytokine release [5], and endothelial
dysfunction [6]. In addition, GV has been associated with
adverse events in other critically ill patient populations
[7-10]. However, the prognostic value of GV has not been
defined in patients with ST-segment elevation myocardial
infarction (STEMI) undergoing primary percutaneous
coronary interventions (p-PCI). Continuous glucose
monitoring systems (CGMS) could provide detailed time
series of consecutive observations on the underlying
process of glucose fluctuations. Such detailed glucose
information to patients has been shown to have positive
influence on glucose control, including reduction in glucose
variability, time spent in nocturnal hypoglycemia, time spent
in hyperglycemia, and levels of glycosylated hemoglobin
[11-13]. The assessment of GV through CGMS is now
much less cumbersome. GV still remains unclear whether
acute glycemic excursion has the important prognostic
significance in AMI patients.
Therefore, the aim of this study was to investigate the
effect of GV on short term prognosis in STEMI patients
undergoing p-PCI.
Materials and methods
Study design and patient population
We enrolled STEMI subjects undergoing p-PCI from two
major hospitals in Beijing, China (Beijing Anzhen Hospital,
Beijing Daxing Hospital, Capital Medical University).
This study was conducted from January 2012 to November
2013. After admission information on previous clinical
history, cardiovascular risk factors, medication were col-
lected in hospital. Moreover, laboratory and echocardiog-
raphy were recorded. The inclusion criteria were: 1)
confirmed admission diagnosis of STEMI undergoing
p-PCI. 2) admission glucose <22.2 mmol/l, and without
diabetic ketosis or nonketotic hyperosmolar coma and 3)
written informed consent. The exclusion criteria included
the following: 1) a history of hepatic or renal impairment,
or of other diseases that can influence glucose metabolism,
including malnutrition, and cancers. 2) without informed
consent. Participants were grouped into diabetes group and
non-diabetes group, and divided into tertiles on the basis of
the mean amplitude of glycemic excursions (MAGE) level
(<2.37 mmol/l, 2.37-3.65 mmol/l and >3.65 mmol/l).
The study protocol was approved by the Medical EthicsCommittee of Beijing Anzhen Hospital, Beijing Daxing
Hospital, Capital Medical University.
Definition of ST-segment elevation myocardial infarction
(STEMI)
ST-segment elevation myocardial infarction was defined as
complaints of chest pain with ECG signs compatible with
acute myocardial infarction (ST-segment elevation >2 mm
in precordial leads and > 1 mm in limb leads) [14]. All
patients were directly transported to the catheterization
laboratory on arrival, and acute coronary angiography was
performed with subsequent PCI when indicated as part of
the routine treatment for all STEMI patients in these
institutions. The interventional strategy was at the opera-
tor’s discretion. Multivessel disease was defined as 70% or
greater stenoses in at least one major epicardial vessel and
50% or greater stenoses in at least one other major vessel.
All patients were pretreated with aspirin, heparin, and
clopidogrel during transportation to the hospital, or these
drugs were administered at the emergency ward [15].
CGMS
All patients were equipped with CGMS (Medtronic
Mini-Med, USA), and were monitored for 72 consecutive
hours after p-PCI. CGMS sensor was inserted in the
abdominal subcutis and calibrated every 6 hours according
to the manufacturer's indications. During the study period,
all subjects were provided standard mixed-meals by dietary
division. The total calorie intake was 126 kJ/kg per day,
with 50% carbohydrates, 15% proteins, and 35% fats. The
calorie distribution between breakfast, lunch, and dinner
was 20%, 40%, and 40%, respectively. Three daily meals
were required to consume at time of 6:30 to 7:30, 11:30 to
12:30, and 18:00 to 19:00, respectively, and each meal had
to be consumed within 30 minutes.
Patients checked their blood glucose level with a
self-monitoring of blood glucose (SMBG) device
(Medisafe Mini, Terumo, Japan) at least 4 times per day.
The sensor measures interstitial glucose every 10 s and
records the mean values at 5-min intervals. The sensor
was left in place for 3 days for collection of data. Adopted
from previous established criteria for optimal accuracy of
the CGMS [16,17], the following criteria for optimal
accuracy included: a correlation between the sensor
and meter readings of at least 0.79, and a mean absolute
difference of no more than 28% (when the daily range
(Min-Max) of meter values ≥5.6 mmol/l); a mean absolute
difference of no more than 18% (when the daily range
(Min-Max) of meter values <5.6 mmol/l).
CGMS parameters: The 24-hour mean BG (24 h MBG)
was calculated as mean BG level from 288 readings
measured by a CGMS over 24 hours. Since measurable
range of glucose by CGMS was mechanically limited from
2.2 to 22.2 mmol/L, the case showing the data out of this
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was calculated as the mean level of 24-hour BG value
(MBG), and intra-day glycemic excursions were calculated
as standard deviation of BG (SDBG) and mean amplitudeTable 1 Clinical characteristics at baseline of study participan
All
Subject number 237
Age (years) 54 ± 16
Males 165 (70)
BMI, kg/m2 25.2 ± 4.6
LVEF, % 53.9 ± 7.3
Systolic BP (mm Hg) 120 ± 21
Diastolic BP (mm Hg) 70 ± 9
Serum creatinine, mg/dL 0.80 ± 0.22
Total Cholesterol (mmol/l) 4.64 ± 1.05
Triglycerides (mmol/l) 2.23 ± 1.28
LDL-C (mmol/l) 2.87 ± 1.10
HDL-C (mmol/l) 0.98 ± 0.31
HbA1c (%) 6.5 ± 1.3
Glycated albumin (%) 17.8 ± 7.6
Peak cTNI (ng/ml) 37.3 ± 10.7
Peak CK-MB (ng/ml) 37.8 ± 15.6
FBG (mmol/l) 7.3 ± 2.8
Management of DM (%)
OHA
Insulin only
Insulin + OHA (s)
Risk factors (n, %)
Hyperlipidemia 93 (39)
Hypertension 95 (40)
Current smoking 106 (45)
Family history 29 (12)
Obesity 55 (23)
CGMS parameters on the first day
MBG (mmol/l) 8.1 ± 2.6
MAGE (mmol/l) 3.6 ± 2.0
SDBG (mmol/l) 1.7 ± 1.0
Angiographic data (n, %)
Single vessel 92 (39)
Double vessels 77 (32)
Triple vessels 68 (29)
Main stem involved 32 (14)
Multivessel 145 (61)
Data given as mean ± SD or n (%).
BMI, body mass index; LVEF, left ventricular ejection fraction; LDL-C, Low density lip
hemoglobin A1c; CK-MB, creatine kinase-MB; cTnI, cardiac troponin I; FBG, fasting b
MAGE, the mean amplitude of glycemic excursions; SDBG, the standard deviation oof glycemic excursion (MAGE). The MAGE was calculated
by measuring the arithmetic mean of the differences
between consecutive peaks and nadirs, provided that the
differences are greater than one standard deviation (SD) ofts
DM Non-DM P-value
73 164 NA
55 ± 17 52 ± 15 0.174
50 (68) 115 (70) 0.801
25.3 ± 4.5 24.8 ± 4.2 0.409
53.5 ± 7.1 54.2 ± 7.4 0.497
123 ± 25 118 ± 23 0.134
69 ± 10 71 ± 12 0.215
0.82 ± 0.21 0.78 ± 0.19 0.149
4.56 ± 1.01 4.69 ± 1.09 0.387
2.36 ± 1.65 1.97 ± 1.03 0.036
2.82 ± 1.13 2.91 ± 1.18 0.584
0.95 ± 0.22 1.01 ± 0.35 0.178
7.1 ± 1.2 6.1 ± 1.0 <0.001
21.2 ± 6.7 12.9 ± 4.5 <0.001
40.5 ± 11.4 36.2 ± 12.5 0.013
39.4 ± 17.5 36.2 ± 16.4 0.176




32 (43.8) 61 (37.2) 0.334
30 (41.1) 65 (39.6) 0.832
30 (41.1) 76 (46.3) 0.453
8 (11) 21 (13) 0.689
20 (27) 35 (21) 0.308
10.6 ± 2.3 6.7 ± 1.1 <0.001
3.9 ± 1.1 2.8 ± 1.6 <0.001
2.5 ± 1.3 1.3 ± 0.7 <0.001
21 (29) 71 (43.3) 0.034
27 (37) 50 (30.5) 0.324
25 (34) 43 (26.2) 0.207
12 (16) 20 (12) 0.378
52 (71) 93 (57) 0.034
oprotein-cholesterol; HDL-C, High density lipoprotein-cholesterol; HbA1c,
lood glucose; OHA, oral hypoglycaemic agent; MBG, Mean blood glucose;
f blood glucose values.
Table 2 Baseline characteristics in AMI patients according
to MAGE
MAGE (mmol/L) <2.37 2.37-3.65 >3.65 P-value
Subject number 80 78 79 NA
Age (years) 51 ± 13 53 ± 15 57 ± 16 0.034
Males 55 (69) 53 (68) 57 (72) 0.831
BMI, kg/m2 24.7 ± 3.9 25.1 ± 4.2 25.4 ± 4.5 0.575
LVEF, % 55.8 ± 7.5 52.5 ± 8.1 51.2 ± 8.4 0.001
Systolic BP (mm Hg) 119 ± 21 121 ± 27 123 ± 25 0.533
Diastolic BP (mm Hg) 70 ± 11 69 ± 12 71 ± 15 0.619
Serum creatinine, mg/dL 0.79 ± 0.25 0.80 ± 0.23 0.82 ± 0.27 0.745
Total Cholesterol (mmol/l) 4.61 ± 1.15 4.63 ± 1.18 4.67 ± 1.09 0.387
Triglycerides (mmol/l) 2.20 ± 1.18 2.18 ± 1.35 2.31 ± 1.43 0.802
HbA1c (%) 6.1 ± 1.4 6.4. ± 1.3 7.0 ± 1.5 <0.001
Glycated albumin (%) 11.8 ± 6.5 16.8 ± 7.7 19.9 ± 8.5 <0.001
Peak CK-MB (ng/ml) 35.1 ± 11.6 37.2 ± 13.4 39.5 ± 14.5 0.113
Peak cTNI (ng/ml) 35.3 ± 12.7 36.9 ± 12.5 40.2 ± 11.4 0.038
MBG (mmol/l) 6.9 ± 1.2 8.1 ± 2.1 9.5 ± 1.9 <0.001
Risk factors (n, %)
Hyperlipidemia 28 (35) 31 (40) 34 (43) 0.580
Hypertension 27 (34) 35 (45) 33 (42) 0.337
Current smoking 31 (39) 33 (42) 42 (53) 0.164
Family history 8 (10) 9 (12) 12 (15) 0.592
Obesity 14 (18) 18 (23) 23 (29) 0.222
Diabetes 11 (14) 20 (26) 42 (53) <0.001
Previous medication
[n (%)]
Aspirin 67 (84) 66 (85) 69 (87) 0.801
ACEI or ARB 45 (56) 48 (62) 50 (63) 0.639
β-Blockers 38 (48) 36 (46) 40 (51) 0.847
Statin 37 (46) 39 (50) 41 (52) 0.769
Angiographic data
[n (%)]
Single vessel 38 (48) 32 (41) 22 (28) 0.035
Double vessels 27 (34) 26 (33) 24 (30) 0.885
Triple vessels 15 (19) 20 (26) 33 (42) 0.005
Main stem involved 8 (10) 11 (14) 13 (16) 0.483
Multivessel 42 (66) 46 (72) 57 (81) 0.037
TIMI-3 flow after PCI 74 (93) 73 (94) 71 (90) 0.678
Data given as mean ± SD or n (%).
BMI, body mass index; LVEF, left ventricular ejection fraction; LDL-C, Low density
lipoprotein-cholesterol; HDL-C, High density lipoprotein-cholesterol; HbA1c,
hemoglobin A1c; CK-MB, creatine kinase-MB; cTnI, cardiac troponin I; FBG, fasting
blood glucose; OHA, oral hypoglycaemic agent; MBG, Mean blood glucose; MAGE,
the mean amplitude of glycemic excursions; SDBG, the standard deviation of
blood glucose values.
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anti-hyperglycemic therapy as usual and be avoided
glucose infusion during CGMS monitoring period.
Otherwise, the patient would be excluded from the study.
After monitoring for 72 hours, the recorded data were
downloaded into a personal computer for analysis of the
glucose profile and glycemic excursion parameters with
the CGMS Software 3.0 (Medtronic MiniMed, Inc.).
Follow-up and definitions of major adverse cardiac events
(MACE)
The primary end point of this study was a composite
MACE defined as the occurrence of one of the following
events: cardiac death, reinfarction, repeat target vessel
revascularization (TVR) after initial revascularization, or
recurrent angina. Patients with more than one event
were assigned the highest ranked event according to the
previous list. Reinfarction was defined as recurrent chest
pain with new ST segment elevation and recurrent
elevation of cardiac enzymes. TVR was defined as
PCI or bypass surgery performed because of reocclusion
of the target vessel. Recurrent angina was defined as
ischemic chest pain with either new ST segment or T wave
changes at rest or on exercise testing. Malignant arrhythmia
was defined as life-threatening cardiac arrhythmias with a
need for resuscitation or pacemaker implantation.
The secondary end point was the incidence of non-infarct
related arteries revascularization during in-hospital
and 30-day follow-up.
All MACE data were adjudicated by an experienced
cardiovascular physician blinded to clinical details and
outcomes.
Statistical analysis
CGM parameters were analyzed using Medtronic MiniMed
CGMS Software 3.0. Data are presented as frequencies and
percentages for categorical variables and mean ± SD for
continuous variables. We used the χ2 to compare the
categorical variables and the 2-sample t test for continuous
variables. Intergroup differences were tested with one-way
analysis of variance (ANOVA). Correlation between
continuous variables was determined by Spearman correl-
ation coefficients. MAGE was included as a continuous
and as a categorized (<2.37 mmol/l, 2.37-3.65 mmol/l
and >3.65 mmol/l) variable. Multivariable logistic regression
analysis was used to assess whether the association between
MAGE and MACE was independent of other factors.
A P value of < 0.05 (two-sided) was considered significant.
Data were analyzed with SPSS 21.0 (Chicago, Illinois).
Results
Based on the inclusion criteria and the exclusion criteria,
we enrolled 247 STEMI patients undergoing p-PCI,
10 cases were excluded for final analysis due to theCGMS signal interruption or not meeting the accuracy
requirements. Data from the remaining 237 subjects
(165 men and 72 women) were incorporated into the
statistical analysis. Table 1 provided the basic characteristics
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subjects had higher levels of Triglycerides, HbA1c,
Glycated albumin(GA) (P < 0.05). MBG, MAGE and SD
were higher in the DM group, compared to non-DM
(P < 0.001). Patients with DM had higher incidences of
multivessel disease (71% vs. 57%, P = 0.034).
Baseline characteristics of patient groups based on
MAGE in the first 24 hours are shown in Table 2. Patients
in the highest MAGE group were older, more likely
to be DM, had more higher levels of HbA1c, GA,
and cTNI than those in the lower MAGE group In
addition, Patients in the highest MAGE group had
higher incidences of triple vessels and multivessel disease,
lower LVEF, higher MBG.
A MAGE profile using the 3 days mean data in diabetic
subjects was shown in Figure 1, the 3 days MAGE mean
values were 3.90 ± 1.1 mmol/l, 3.34 ± 1.25 mmol/l, 3.16 ±
1.15 mmol/l, respectively (p = 0.001). Figure 2 showed the
MAGE profile using the 3 days mean data in nondiabetic
subjects, the 3 days MAGE mean values were 2.80 ±
1.6 mmol/l, 2.43 ± 1.62 mmol/l, 2.39 ± 1.49 mmol/l, re-
spectively (p = 0.034).
Figures 3 and 4 showed a statistically significant
correlation between peak CK-MB values and MAGE values
of the first day in diabetic subjects (r = 0.64, p <0.001) and
nondiabetic subjects (r = 0.519, p < 0.001). Moreover,
Figures 5 and 6 also revealed a statistically significant
correlation between peak cTnI values and MAGE values ofFigure 1 MAGE values for 3 days through using CGMS in diabetic subthe first day in diabetic subjects (r = 0.644, p < 0.001)
and nondiabetic subjects (r = 0.654, P <0.001). Compared
with non-diabetes patients, DM subjects had higher
incidence of composite MACE (24.7% vs. 10.4%, p = 0.004),
recurrent angina (12.3% vs. 3.7%, p = 0.025), and non-IRA
revascularization (37% vs. 16%, p = 0.001) (Table 3).
Table 4 and Figure 7 revealed the clinical outcome of
study patients during in-hospital and 30-day follow-up.
The results showed 4 patients had died (1.7%) for cardiac
causes, 3 patients had reinfarction (1.3%), and 3 patients
had repeat TVR (1.3%), 15 patients had recurrent angina
(6.3%), 10 patients had malignant arrhythmia (4.2%),
1 patients had died for non-cardiac causes (0.4%), 53
patients had non-IRA revascularization (22.4%). As
expected, STEMI patients with MAGE level >3.65 mmol/L
had significantly higher incidence of composite MACE
compared with STEMI patients with MAGE level from
2.37 mmol/L to 3.65 mmol/L, or < 2.37 mmol/L (22.8% vs.
14.1% vs. 7.5%, p = 0.025). STEMI patients with a higher
MAGE level had a significantly higher non-IRA revas-
cularization compared with those with lower MAGE
levels (32% vs. 15% vs. 21%, p = 0.037).
Moreover, compared with DM patients with MAGE
level < 2.84 mmol/L, or 2.84 mmol/L to 3.96 mmol/L,
DM patients with MAGE level >3.96 mmol/L had
significantly higher incidence of composite MACE
(8.3% vs. 25% vs. 40%, p = 0.038), and non-IRA revas-
cularization (15% vs. 21% vs. 32%, p = 0.037) (Table 5).jects.
Figure 2 MAGE values for 3 days through using CGMS in nondiabetic subjects.
Figure 3 Correlation of peak CK-MB values and MAGE values of the first day in diabetic subjects.
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Figure 4 Correlation of peak CK-MB values and MAGE values of the first day in nondiabetic subjects.
Figure 5 Correlation of peak cTnI values and MAGE values of the first day in diabetic subjects.
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Figure 6 Correlation of peak cTnI values and MAGE values of the first day in nondiabetic subjects.
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higher MAGE level did not reveal significant differences
in the incidence of composite MACE and non-IRA
revascularization.
Multivariate analysis of glucose variability and MACE
Multivariable logistic regression analysis was used to assess
whether the association between MAGE and composite
MACE was independent of other factors in diabetic
and nondiabetic subjects. We chose variables that
were significantly different between MAGE categories asTable 3 Clinical Outcome during in-hospital and 30-day
follow-up in diabetic and non-diabetic patients
DM Non-DM P
Subject number (n) 237 73 164 NA
Composite MACE 35 (14.8) 18 (24.7) 17 (10.4) 0.004
Cardiac death 4 (1.7) 2 (2.7) 2 (1.2) 0.770
Reinfarction 3 (1.3) 2 (2.7) 1 (0.6) 0.469
Repeated TVR 3 (1.3) 1 (1.4) 2 (1.2) 0.594
Recurrent angina 15 (6.3) 9 (12.3) 6 (3.7) 0.025
Malignant arrhythmia 10 (4.2) 5 (6.8) 5 (3) 0.320
Non-cardiac death 1 (0.4) 0 (0) 1 (0.6) 0.678
Non-IRA revascularization 53 (22.4) 27 (37) 26 (16) 0.001
Data given as mean ± SD or n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse
cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.co-factors. Include variables were: age, LVEF, HbA1c, GA,
Peak cTNI, MBG, and MAGE. The independent predictors
of MACE in diabetic subjects were: LVEF (OR 0.829,
95% CI 0.702-0.980, p = 0.028), MBG (OR 2.076, 95%
CI 1.077-4.003, p = 0.029), and MAGE (OR 2.857, 95%
CI 1.143- 7.139, p = 0.025). Other factors were not signifi-
cantly associated with MACE: Age (OR 1.055, 95% CI
0.952-1.169, p = 0.310), GA (OR 1.309, 95% CI0.847-2.023,
p = 0.225), peak cTNI (OR 1.064, 95% CI 0.726-1.559,
p = 0.751), and HbA1c (OR 1.337, 95% CI 0.713-2.507,Table 4 Clinical Outcome of study patients during
in-hospital and 30-day follow-up based on MAGE levels
MAGE (mmol/L) <2.37 2.37-3.65 >3.65 P
Subject number (n) 237 80 78 79 NA
Composite MACE 35 (14.8) 6 (7.5) 11 (14.1) 18 (22.8) 0.025
Cardiac death 4 (1.7) 1 (1.3) 1 (1.3) 2 (2.5) 0.775
Reinfarction 3 (1.3) 0 (0) 1 (1.3) 2 (2.5) 0.361
Repeated TVR 3 (1.3) 0 (0) 1 (1.3) 2 (2.5) 0.361
Recurrent angina 15 (6.3) 3 (3.8) 5 (6.4) 7 (8.9) 0.416
Malignant arrhythmia 10 (4.2) 2 (2.5) 3 (3.8) 5 (6.3) 0.477
Non-cardiac death 1 (0.4) 0 (0) 1 (1.3) 0 (0) 0.359
Non-IRA
revascularization
53 (22.4) 12 (15) 16 (21) 25 (32) 0.037
Data given as mean ± SD or n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse
cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.
Figure 7 Incidence of MACE during in-hospital and 30-day follow-up.
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MACE in nondiabetic subjects were: MBG (OR1.627, 95%
CI 1.077-2.458, p = 0.021), and MAGE (OR 2.097, 95%
CI 1.093-4.026, p = 0.026). Other factors were not signifi-
cantly associated with MACE (Table 8).
Discussion
In-hospital hyperglycemia portends a poor prognosis in
AMI patients [18-24]; however, the prognostic significance
of GV after AMI remains controversial. Some studies
showed that GV was related to cardiovascular risk [18-20].
However, other studies did not showed similar results.
The reanalysis of the Diabetes Control and Complications
Trial (DCCT) and DCCT/Epidemiology of Diabetes
Interventions and Complications (EDIC) dataset examin-
ing the predictive value of GV on microvascular and
neurologic complications did not show an effect of GV
independent from mean glucose and HbA1c [21-23]. TheTable 5 Clinical Outcome of diabetes subjects based on
MAGE levels during in-hospital and 30-day follow-up
MAGE (mmol/L) <2.84 2.84-3.96 >3.96 P
Subject number (n) 73 24 24 25 NA
Composite MACE 18 (24.7) 2 (8.3) 6 (25) 10 (40) 0.038
Non-IRA revascularization 27 (37) 4 (15) 10 (21) 13 (32) 0.032
Data given as n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse
cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.results of reanalysis of the HEART2D study showed a
decrease in GV did not reduce cardiovascular events in
patients with type 2 DM after AMI [24]. These previous
studies focused on diabetes patients and did not included
non-diabetes subjects, moreover, many diabetic patients
were treated with insulin and insulin per se could inhibit
oxidative stress. It might be possible that these negative
results were explained by type 2 diabetic patients with
advanced atherosclerosis and patients with diabetes, in
contrast with critically ill patients without previously
diagnosed diabetes, were not affected by GV because of
the ability of cells to adapt to the harmful effects of
changing ambient glucose [7] and insulin per se neutralize
the deleterious effects of GV on oxidative stress in patients
treated with it [25].
One prior study evaluated the role of GV on in-hospital
mortality of patients with AMI. The results of thisTable 6 Clinical Outcome of non-diabetes subjects based
on MAGE levels during in-hospital and 30-day follow-up
MAGE (mmol/L) <2.21 2.21-3.38 >3.38 P
Subject number (n) 164 55 55 54 NA
Composite MACE 17 (10.4) 4 (7.3) 6 (10.9) 7 (13) 0.614
Non-IRA
revascularization
26 (15.9) 7 (12.7) 9 (16.4) 10 (18.5) 0.704
Data given as mean ± SD or n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse
cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.
Table 7 Multivariable logistic regression to evaluate
independent factors on composite MACE in diabetic
subjects
Variable OR 95% confidence interval P
Age 1.055 0.952-1.169 0.310
LVEF 0.829 0.702-0.980 0.028
Peak cTNI 1.064 0.726-1.559 0.751
HbA1C 1.337 0.713-2.507 0.365
GA 1.309 0.847-2.023 0.225
MBG 2.076 1.077-4.003 0.029
MAGE 2.857 1.143-7.139 0.025
OR = Odds ratio; other abbreviations the same as for Tables 1, 2 and 3.
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with increased risk of in-hospital mortality in patients
with AMI in unadjusted analyses, GV was no longer
independently predictive after controlling for multiple
patient factors [26]. In addition, subgroup analyses by
STEMI versus NSTEMI status showed that higher GV
was associated with significantly increased mortality
risk in patients with STEMI but not in patients with
NSTEMI [26]. Su G et al. reported that the early in-hospital
GV was an important predictor of mortality and MACE
even stronger than HbA1c in elderly patients after AMI
[27]. Whether GV plays a special role in patients with
STEMI or whether it is simply a prognostic marker remains
unclear. So our aim is to assess the prognostic value
of GV in STEMI patients undergoing p-PCI. The results
of our study showed GV was associated with Composite
MACE and non-IRA revascularization. However, our
findings, from the subgroup analysis, suggested diabetic
subjects with a higher MAGE level had significantly
higher incidence of composite MACE and non-IRA
revascularization compared with those with lower MAGE
levels, but non-diabetic subjects did not show the similar
results. These results remained controversial. A systematic
review of glycemic variability and complications in
patients with diabetes mellitus showed a significant
positive association between glucose variability andTable 8 Multivariable logistic regression to evaluate
independent factors on composite MACE in nondiabetic
subjects
Variable OR 95% confidence interval P
Age 1.025 0.940-1.117 0.582
LVEF 0.914 0.803-1.041 0.176
Peak cTNI 1.063 0.810-1.395 0.661
HbA1C 1.244 0.696-2.225 0.461
GA 1.121 0.857-1.467 0.403
MBG 1.627 1.077-2.458 0.021
MAGE 2.097 1.093-4.026 0.026
OR = Odds ratio; other abbreviations the same as for Tables 1, 2 and 3.the development or progression of diabetic retinopathy,
cardiovascular events and mortality, and glucose
variability could be a predictor of diabetic complications,
independent of HbA1c levels in patients with type 2 DM
[19]. Another study thought that a deleterious effect
resulting from increased glycemic variability was noted
among non-diabetic patients, but not among patients with
diabetes [28]. In our study the number of study patients
was relatively small and the clinical follow-up time was
short, which maybe impact the results and need further
research in the future. Moreover, multivariable logistic
regression analysis showed MAGE, MBG were independent
predictors of MACE in diabetic and nondiabetic subjects
and HbA1c and GA were not.
CGMS could be the best method to show trends and
predict impending glucose excursions and to monitor
GV. MAGE was considered as the “gold standard” of
glycemic variability [4]. In our study MAGE was calculated
through CGMS data. Our study demonstrates that elevated
MAGE is an independent predictor of increased risk of
MACE in AMI patients. There were major differences in
baseline characteristics according to MAGE level. Patients
with higher MAGE had more cardiovascular risk factors,
such as older age, diabetes. Moreover, patients with higher
MAGE had higher peak CK-MB values and peak cTNI
values, there was also a clear correlation between MAGE
and peak CK-MB values or peak cTNI values, which reflect
the severity and size of myocardial necrosis. Angiographic
data showed triple vessels and multivessel lesions were
more common in patients with higher MAGE. These
results indicate that AMI patients with higher GV
may be associated with poorer outcomes.
Stress hyperglycaemia is common in acute myocardial
infarction, whereas increased catecholamine levels result in
decreased insulin secretion and increased insulin resistance
[29]. Although stress-induced hyperglycaemia could partly
explain the relation between admission GV and outcomes,
especially for AMI patients, glycemic excursion itself can
also be harmful. Ceriello et al. reported that intermittent
hyperglycaemia induced a higher degree of apoptosis in
endothelial cells than chronic hyperglycaemia [30].
Quagliaro et al. showed that the apoptosis of endothelial
cells exposed to intermittent hyperglycaemia may be
related to a reactive oxygen species (ROS) overproduction,
through protein kinase C (PKC)-dependent activation
of nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase [31]. Both acute and chronic blood glucose variabil-
ity can induce oxidative stress and chronic inflammation.
Moreover, severe glycemic disorders may adversely affect
sympathetic dysfunction which is associated with mortality
and morbidity of cardiovascular disease [32]. Following
the use of CGMS the GV can be accurately and conveni-
ently calculated. Although the prognostic value of GV in
AMI patients remains controversial, but GV may be an
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Further studies are needed to investigate the impact of
GV on long-term prognosis for STEMI patients and
NONSTEMI patients.Study limitations
There are several limitations to this study. First, the
number of patients was relatively small, so that comparisons
of some subgroups might lack power to detect significant
differences for selected variables. Second, although we had
avoided glucose infusion during CGMS monitoring period,
but due to dietary irregular and could not analyze the
postprandial BG levels. Moreover, some other factors,
such as physical and emotional factors, which maybe
affect the result of GV. Third, we are not enrolled all
STEMI patients, only enrolled STEMI patients undergoing
p-PCI, so maybe miss many critical AMI patients and
affect the outcomes. Hence the results of the present study
should be interpreted with caution.Conclusions
At present the prognostic value of GV in AMI patients
remains unclear, our study has revealed that in STEMI
patients undergoing p-PCI greater GV is associated with
composite MACE and non-IRA revascularization during
in-hospital and 30-day follow-up, especially for diabetic
subjects. Further studies are needed to investigate whether
reducing GV will reduce cardiovascular risk independently
from already recognized risk factors and observe the
impact of GV on long-term prognosis for STEMI patients
undergoing p-PCI.
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